A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects with Advanced Recurrent Ovarian Cancer Save

Date Added
April 12th, 2016
PRO Number
Pro00052959
Researcher
Jennifer Young
Keywords
Cancer, Cancer/Gynecological, Drug Studies, Obstetrics and Gynecology, Women's Health
Summary

This study will assess the efficacy and safety of pembrolizumab (MK-3475) in women with advanced ovarian cancer who have demonstrated recurrent disease following the front line platinum-based treatment and debulking surgery and received up to 5 lines of treatment for recurrent ovarian cancer (ROC) per local standard of care. Participants will receive pembrolizumab every 3 weeks (Q3W) for up to 2 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Save

Date Added
February 9th, 2016
PRO Number
Pro00050262
Researcher
Whitney Graybill
Keywords
Cancer, Cancer/Gynecological, Drug Studies, Obstetrics and Gynecology, Women's Health
Summary

This study is for female subjects with previously untreated Stage III or IV high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. The investigational drug in this study is Veliparib (ABT-888). The purpose of this study is to compare the combination of carboplatin, paclitaxel and veliparib to carboplatin, paclitaxel, and placebo followed by continued therapy with either veliparib or placebo to determine if it slows the progression of your cancer.

Institution
MUSC
Recruitment Contact
HCC Clincial Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer Save

Date Added
May 12th, 2015
PRO Number
Pro00043131
Researcher
Whitney Graybill
Keywords
Cancer, Cancer/Gynecological, Drug Studies, Women's Health
Summary

This study is for patients that have been diagnosed with platinum-sensitive ovarian cancer.The investigational drug in this study is Farletuzumab. The main purpose of this study is to find out if carboplatin plus paclitaxel or carboplatin plus Pegylated Liposomal Doxorubicin (PLD), chemotherapies (anticancer drugs) that are used to treat ovarian cancer, work better alone or when given with an farletuzumab.
The estimated total duration of this study will be approximately 46 months (1 month screening, 15 months treatment, and 30 months follow-up). The actual total duration will vary depending on subject response to drug and disease progression

Institution
MUSC
Recruitment Contact
Vistea Crawford
843-792-6429
crawforv@musc.edu

A RANDOMIZED TRIAL OF PELVIC IRRADIATION WITH OR WITHOUT CONCURRENT WEEKLY CISPLATIN IN PATIENTS WITH PELVIC-ONLY RECURRENCE OF CARCINOMA OF THE UTERINE CORPUS Save

Date Added
December 16th, 2014
PRO Number
Pro00039931
Researcher
Jeffrey Elder
Keywords
Cancer, Cancer/Gynecological, Obstetrics and Gynecology, Women's Health
Summary

This is a Phase II study for women diagnosed with pelvic-only and or vaginal recurrence of endometrial cancer following complete hysterectomy and bilateral salpingo-oophorectomy at the time of initial diagnosis . Patients will be randomized to receive external pelvic radiation for approximately 5 weeks followed by brachytherapy OR external pelvic radiation for approximately 5 weeks plus weekly chemotherapy with cisplatin followed by brachytherapy. The study is designed as a screening study to estimate the benefit on progression-free survival of the addition of cisplatin to external pelvic irradiation, overall survival, side effects and evaluate factors at study entry and from original hysterectomy as potential prognostic factors.

Institution
Greenville
Recruitment Contact
Anna Polan
8645222063
apolan@ghs.org

Can Diet and Physical Activity Modulate Ovarian Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Save

Date Added
November 18th, 2014
PRO Number
Pro00039133
Researcher
Jennifer Young
Keywords
Cancer/Gynecological
Summary

This study is for women who have completed treatment (chemotherapy and other treatment) for state II, III, or IV ovarian, fallopian tube or primary peritoneal cancer (cancer having to do with the tissue that lines the inside of the abdomen and covers its organs) and are at risk for the cancer coming back.

Institution
MUSC
Recruitment Contact
Sarah Booker
843-792-9190
bookers@musc.edu

Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis Save

Date Added
August 5th, 2014
PRO Number
Pro00036914
Researcher
Patricia Griffin
Keywords
Bone, Cancer, Cancer/Brain, Cancer/Breast, Cancer/Gastrointestinal, Cancer/Genitourinary, Cancer/Gynecological, Cancer/Head & Neck, Cancer/Leukemia, Cancer/Lung, Cancer/Lymphoma, Cancer/Myeloma, Cancer/Other, Cancer/Sarcoma, Cancer/Skin, Spinal Cord
Summary

Multiple radiation treatments are frequently used to treat pain caused by cancer that has spread to the spine. Image-guided radiosurgery/stereotactic body radiation therapy (SBRT) is a treatment that uses highly focused x-rays to deliver a single high dose on a specific area of the body. Image-guided radiosurgery/SBRT uses special equipment to position the patient and guide the focused beams toward the area to be treated and away from normal tissue.

The purpose of this part of the study is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.

Institution
Spartanburg
Recruitment Contact
Clinical Research Department
1-800-486-5941
research@srhs.com

A pilot study evaluating vitamin D deficiency and risk of aggressive uterine cancer in African American as compared to White women Save

Date Added
May 19th, 2014
PRO Number
Pro00030938
Researcher
Whitney Graybill
Keywords
Cancer/Gynecological, Women's Health
Summary

The purpose of this study is to evaluate vitamin D levels in African American and White women who present with a new diagnosis of uterine cancer.

Institution
MUSC
Recruitment Contact
Tamara Saunders
843-792-6992
saundert@musc.edu

A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #120636) In Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression Save

Date Added
May 6th, 2014
PRO Number
Pro00033486
Researcher
David Griffin
Keywords
Cancer, Cancer/Gynecological, Drug Studies
Summary

This phase II trial studies how well dasatinib works in treating patients with persistent ovarian, fallopian tube, endometrial, or peritoneal cancer. Dasatinib may shrink patients' tumors by blocking some of the enzymes needed for cell growth.

Institution
Spartanburg
Recruitment Contact
Clinical Research Department
1-800-486-5941
research@srhs.com

A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Save

Date Added
April 30th, 2014
PRO Number
Pro00034096
Researcher
Whitney Graybill
Keywords
Cancer/Gynecological, Women's Health
Summary

This study is for adult women who have advanced or recurrent endometrial (uterine) cancer. The purpose is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating uterine cancer.

Institution
MUSC
Recruitment Contact
Sarah Booker
843-792-9190
bookers@musc.edu

A Phase II Trial Evaluating Cisplatin (NSC#119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva Save

Date Added
May 23rd, 2013
PRO Number
Pro00025562
Researcher
David Griffin
Keywords
Cancer, Cancer/Gynecological, Drug Studies
Summary

The purpose of this study is to find out if radiation therapy along with the addition of the drugs, cisplatin and gemcitabine, works in treating locally advanced squamous cell carcinoma of the vulva and to find out what side effects or surgical complications are caused by treatment with this combination.

Institution
Spartanburg
Recruitment Contact
Clinical Research Department
1-800-486-5941
research@srhs.com

Change_preferences

-- OR --

Create_login